Invited Mini Review

Remodeling of host glycoproteins during bacterial infection

Yeolhoe Kim^{1,2}, Jeong Yeon Ko^{1,2} & Won Ho Yang^{1,2,*}¹Department of Systems Biology, BK21 Plus Project, College of Life Science and Biotechnology, Yonsei University, Seoul 03722,²Glycosylation Network Research Center, Yonsei University, Seoul 03722, Korea

Protein glycosylation is a common post-translational modification found in all living organisms. This modification in bacterial pathogens plays a pivotal role in their infectious processes including pathogenicity, immune evasion, and host-pathogen interactions. Importantly, many key proteins of host immune systems are also glycosylated and bacterial pathogens can notably modulate glycosylation of these host proteins to facilitate pathogenesis through the induction of abnormal host protein activity and abundance. In recent years, interest in studying the regulation of host protein glycosylation caused by bacterial pathogens is increasing to fully understand bacterial pathogenesis. In this review, we focus on how bacterial pathogens regulate remodeling of host glycoproteins during infections to promote the pathogenesis. [BMB Reports 2021; 54(11): 541-544]

INTRODUCTION

Protein glycosylation, a well-known post-translational modification found in all living organisms, affects a wide range of protein properties including folding, stability, enzyme activity, interactions, signal transduction, tissue targeting, and resistance to proteolysis (1-3). Protein glycosylation plays an essential role in diverse functions of the immune system. Therefore, glycans are reasonable targets for bacterial pathogenesis. Glycans in the immune system have various roles such as protecting proteins from proteases, regulating protein interactions, and contributing to protein activity and stability (4, 5). In eukaryote organisms, protein glycosylation has two major forms: N-linked and O-linked glycosylation. Both glycosylation systems have been also identified in pathogenic bacteria (6, 7). Glycosylated molecules such as glycoproteins, capsular polysaccharides, and lipooligosaccharides or lipopolysaccharides on pathogenic bacteria are presented to the host. They are involved in the colo-

nization, pathogenicity, and virulence (8). Glycans on the host cell surface are used by many bacterial pathogens for adhesion, nutrients, and targets of toxins (1, 8-10). Recently, studies on the mechanisms by which pathogenic bacteria can regulate host glycosylation are increasing to understand the pathogenic mechanism in host immune system. Bacterial glycosyltransferases and glycosidases can modify host protein glycosylation for the pathogenic process. Furthermore, pathogenic bacterial infection can modify host glycans by activating host glycosyltransferases and glycosidases. In this short review, we will discuss how bacterial infections remodel host protein glycosylation that has a pivotal role in bacterial pathogenesis and host immune system.

ALTERATIONS IN HOST GLYCOSYLATION BY BACTERIAL GLYCOSYLTRANSFERASES AND GLYCOSIDASES

Bacterial pathogens can modify host protein glycosylation using various bacterial glycosyltransferases and glycosidases (Table 1). The modification of host glycans gives bacterial pathogens host adaptation functions including nutrients acquisition and cell attachment (8). Neuraminidases (sialidases) are well-known modifying enzymes that can cleave sialic acid from glycans. Many types of bacteria produce neuraminidase with various specificities (11). *Streptococcus pneumoniae*, a common cause of sepsis, can produce neuraminidase to induce rapid desialylation and clearance of platelets during systemic *S. pneumoniae* infection (12). Host danger-associated molecular patterns (DAMPs) can diminish pro-inflammatory TLR signaling by forming a complex with sialylated CD24 and SiglecG/10. However, sialidases from *S. pneumoniae* can disrupt the CD24-SiglecG/10 inhibitory complex and lead to elevated cytokine production through cleaving sialic acids on CD24 during *S. pneumoniae* sepsis (13, 14). A cell surface neuraminidase of *Treponema denticola*, an oral spirochete, can remove sialic acids on human serum glycoprotein for bacterial growth (15).

Besides bacterial neuraminidases that are well characterized, other bacterial glycosidases can also modify host glycoproteins. Endoglycosidase S (EndoS) from *Streptococcus pyogenes*, a cause of necrotizing fasciitis and streptococcal toxic shock, can hydrolyze glycans from host IgG to evade host adaptive immunity (16, 17). EndoE from *Enterococcus faecalis*, a cause of nosocomial infection, can cleave glycans of host IgG, RNase B,

*Corresponding author. Tel: +82-2-2123-2657; Fax: +82-2-312-5657; E-mail: bionicwono@yonsei.ac.kr

<https://doi.org/10.5483/BMBRep.2021.54.11.129>

Received 20 August 2021, Revised 13 October 2021,
Accepted 20 October 2021

Keywords: Bacterial infection, Pathogenesis, Protein glycosylation, Remodeling

Table 1. Bacterial glycosyltransferases and glycosidases discussed in this review

Bacterial pathogen	Bacterial glycosyltransferase or glycosidase	Host substrate	Reference
<i>Streptococcus pneumoniae</i>	Sialidase	Platelets, CD24	(12-14)
<i>Treponema denticola</i>	Sialidase	Serum glycoprotein	(15)
<i>Streptococcus pyogenes</i>	Endoglycosidase S (EndoS)	IgG	(16, 17)
<i>Enterococcus faecalis</i>	Endoglycosidase E (EndoE)	IgG, RNase B, lactoferrin	(18, 19)
<i>Capnocytophaga canimorsus</i>	Endo- β -N-acetylglucosaminidase (GpdG)	IgG	(20)
Enteropathogenic <i>E. coli</i>	arginine glycosyltransferase NleB	Fas-associated via death domain (FADD) proteins	(21-23)
<i>Phototaxillus asymbiotica</i>	PaTox	Rho GTPases	(24)
<i>Legionella pneumophila</i>	<i>Legionella</i> glucosyltransferase	eEF1A	(25, 26)
<i>Clostridium difficile</i>	TcdA and TcdB glucosyltransferase	Rho (RhoA/B/C), Rac (Rac1-3), and Cdc42	(27, 28)

Table 2. Bacterial pathogen-induced activation of host glycosyltransferases and glycosidases discussed in this review

Bacterial pathogen	Host glycosyltransferase or glycosidase	Host substrate	Reference
<i>Helicobacter pylori</i>	β 1,3-galactosyltransferase	IgA	(29, 30)
<i>Salmonella enterica</i> Typhimurium	Sialidase	Intestinal alkaline phosphatase	(32)
<i>Salmonella</i> , <i>E. coli</i>	Sialidase	Circulating alkaline phosphatase isozymes	(33)
<i>Francisella tularensis</i>	B3GNT2, B3GNT3, B4GALT1, B4GALT3, B4GALT5, C1GALT1, GALNT2, GALNT11, ST3GAL1, Hexosaminidase A, EDEM1, EDEM2, EDEM3, GANAB	Various N-glycosylproteins and O-glycosylproteins	(34)
<i>Salmonella typhimurium</i> , <i>Helicobacter bilis</i> , <i>Citrobacter rodentium</i>	Fucosyltransferase 2	Intestinal epithelial glycoproteins	(35-38)

and lactoferrin for modulating host immune responses and bacterial growth (18, 19). *Capnocytophaga canimorsus* is detected in the saliva of healthy dogs and cats. However, it can cause illness in humans. Endo- β -N-acetylglucosaminidase (GpdG) of the N-glycan glycoprotein deglycosylation complex from *C. canimorsus* can deglycosylate human IgG to use released sugars as nutrients for bacterial growth (20).

Enteropathogenic *E. coli* use type III secretion systems for translocating effector proteins into host cells. One such effector is arginine glycosyltransferase NleB that catalyzes arginine GlcNAcylation of Fas-associated via death domain (FADD) proteins to block host defense (21-23). Entomopathogenic *Phototaxillus asymbiotica* is an emerging human pathogen. *P. asymbiotica* protein toxin (PaTox) with a glycosyltransferase domain can induce tyrosine-O-glycosylation of host Rho GTPases by using UDP-GlcNAc, resulting in actin disassembly, inhibition of phagocytosis, and toxicity toward host cells (24). *Legionella pneumophila* infection causes Legionnaires' disease pneumonia. *Legionella* glucosyltransferase proteins are *Legionella* virulence factors with UDP-glucosyltransferase activity. They can inhibit host protein synthesis through eEF1A (eukaryotic elongation factor 1A) glucosylation, resulting in host cell death (25, 26). *Clostridium difficile* is associated with hospital-acquired infect-

ious diarrhea and pseudomembranous colitis. It produces toxin A (TcdA) and toxin B (TcdB) as predominant virulence factors (27). TcdA and TcdB are internalized into host cells. The glycosyltransferase domain of these toxins is then released into the cytosol, where Rho GTPases including Rho (RhoA/B/C), Rac (Rac1-3), and Cdc42 are mono-O-glucosylated and inactivated, resulting in impaired epithelial barrier functions, inflammation, and host cell death (28).

REMODELING OF HOST GLYCOPROTEINS BY THE ACTIVATION OF HOST GLYCOSYLTRANSFERASES AND GLYCOSIDASES DURING BACTERIAL INFECTIONS

Bacterial pathogens can modify host protein glycosylation by modulating the expression of numerous host glycosyltransferases and glycosidases (Table 2). *Helicobacter pylori*, a cause of gastrointestinal diseases such as chronic gastritis and gastric cancer, is related to IgA nephropathy. Cytotoxin associated gene A protein (CagA), a major virulence factor of *Helicobacter pylori*, can promote abnormal glycosylation of host IgA by downregulating host β -1,3-galactosyltransferase. Abnormal glycosylation of IgA is involved in the pathogenesis of IgA nephro-

pathy (29, 30). Recurrent nonlethal gastric infections of *Salmonella enterica* Typhimurium, a leading cause of human food poisoning, can induce chronic intestinal inflammation in a mouse model. The disease mechanism involves the deficiency of intestinal alkaline phosphatase (IAP), which can dephosphorylate and detoxify the lipopolysaccharide (LPS) endotoxin produced by commensal Gam-negative microbiota in the host (31, 32). Recurrent *S. enterica* Typhimurium reinfection can induce host endogenous neuraminidase activity, which accelerates the desialylation and clearance of IAP. The administration of zanamivir, an antiviral neuraminidase inhibitor, has therapeutic effect through maintaining IAP abundance and function (32). In mouse experimental sepsis elicited by Gram-negative *Salmonella* and *E. coli*, a host protective mechanism through LPS detoxification by circulating alkaline phosphatase (AP) isozymes is debilitated through host neuraminidase induction (33). Increased neuraminidase activity can accelerate the clearance of AP isozymes mediated by the hepatic lectin Ashwell-Morell receptor. The inhibition of neuraminidase activity can diminish inflammation and promote host survival (33). The bacterial pathogen *Francisella tularensis* is an agent of zoonotic disease tularemia. It can modulate numerous host glycosyltransferases and glycosidases such as β -N-acetylglucosaminyltransferase B3GNT2, B3GNT3, β -galactosyltransferase B4GALT1, B4GALT3, B4GALT5, N-acetylgalactosamine- β -galactosyltransferase C1GALT1, N-acetylgalactosaminyltransferase GALNT2, GALNT11, α -2,3-Sialyltransferase ST3GAL1, Hexosaminidase A, ER Degradation Enhancing Alpha-Mannosidase Like Protein EDEM1, EDEM2, EDEM3, and glucosidase II α subunit GANAB. It can also modify various N-glycosylproteins and O-glycosylproteins, including the multifunctional ER chaperone binding immunoglobulin protein (BiP) (34). Pathogenic bacteria such as *Salmonella typhimurium*, *Helicobacter bilis*, and *Citrobacter rodentium* can induce intestinal epithelial fucosyltransferase 2 expression and α 1,2-fucosylation. The intestinal epithelial α 1,2-fucosylation is important for various immune reactions, including host defense and host-commensal bacteria interplay (35-38).

CONCLUDING REMARKS

A large number of pathogenic bacterial glycosyltransferases and glycosidases have been discovered and characterized. Functions of these enzymes on glycans of host key proteins in the immune system contribute to the pathogenesis of bacterial pathogens through increased adhesion, nutrient acquisition, targets of bacterial toxins, evading the immune response, and persisting bacterial survival in the host. In addition, bacterial pathogens can modify glycans on many key proteins in host immune system through inducing various host glycosyltransferases and glycosidases, thus contributing to the pathogenesis. Alteration in protein glycosylation can affect protein activity, abundance, stability, and interaction with other proteins regardless whether glycosyltransferases and glycosidases come from bacterial pathogens or hosts. Thus, it is an essential step

to analyze remodeling of host glycoprotein during bacterial infection to fully understand the pathogenesis. Although it is difficult to understand bacterial modulation of host glycosylation while bacterial infections induce various host glycosyltransferases and glycosidases, recent advances in glycoengineering make it possible to thoroughly analyze remodeling of host glycans. Taken together, this study about remodeling of host glycoproteins during bacterial infection provides potentially a new insight into bacterial pathogenesis and an opportunity to develop novel therapeutic and preventive strategies to fight infectious diseases.

ACKNOWLEDGEMENTS

This work was supported by the Yonsei Research Fund (2019-22-0020) and the National Research Foundation of Korea (NRF) Ministry of Science, ICT and Future Planning NRF-2016R1A5A1010764 and NRF-2020R1A2C101232911.

CONFLICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

1. Bhat AH, Maity S, Giri K and Ambatipudi K (2019) Protein glycosylation: sweet or bitter for bacterial pathogens? Crit Rev Microbiol 45, 82-102
2. Moremen KW, Tiemeyer M and Nairn AV (2012) Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol 13, 448-462
3. Pinho SS and Reis CA (2015) Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 15, 540-555
4. Rudd P, Elliott T, Cresswell P, Wilson I and Dwek R (2001) Glycosylation and the immune system. Science 291, 2370-2376
5. Sjögren J and Collin M (2014) Bacterial glycosidases in pathogenesis and glycoengineering. Future Microbiol 9, 1039-1051
6. Nothhaft H and Szymanski CM (2010) Protein glycosylation in bacteria: sweeter than ever. Nat Rev Microbiol 8, 765-778
7. Szymanski CM and Wren BW (2005) Protein glycosylation in bacterial mucosal pathogens. Nat Rev Microbiol 3, 225-237
8. Poole J, Day CJ, von Itzstein M, Paton JC and Jennings MP (2018) Glycointeractions in bacterial pathogenesis. Nat Rev Microbiol 16, 440-452
9. Jank T, Belyi Y and Aktories K (2015) Bacterial glycosyltransferase toxins. Cell Microbiol 17, 1752-1765
10. Lu Q, Li S and Shao F (2015) Sweet talk: protein glycosylation in bacterial interaction with the host. Trends Microbiol 23, 630-641
11. Sudhakara P, Sellamuthu I and Aruni AW (2019) Bacterial sialoglycosidases in virulence and pathogenesis. Pathogens 8, 39

12. Grewal PK, Uchiyama S, Ditto D et al (2008) The Ashwell receptor mitigates the lethal coagulopathy of sepsis. *Nat Med* 14, 648-655
13. Chen GY, Chen X, King S et al (2011) Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. *Nat Biotechnol* 29, 428-435
14. Paulson JC and Kawasaki N (2011) Sialidase inhibitors DAMPen sepsis. *Nat Biotechnol* 29, 406-407
15. Kurniyati K, Zhang W, Zhang K and Li C (2013) A surface-exposed neuraminidase affects complement resistance and virulence of the oral spirochaete *Treponema denticola*. *Mol Microbiol* 89, 842-856
16. Collin M and Olsén A (2001) EndoS, a novel secreted protein from *Streptococcus pyogenes* with endoglycosidase activity on human IgG. *EMBO J* 20, 3046-3055
17. Naegeli A, Bratanis E, Karlsson C et al (2019) *Streptococcus pyogenes* evades adaptive immunity through specific IgG glycan hydrolysis. *J Exp Med* 216, 1615-1629
18. Collin M and Fischetti VA (2004) A novel secreted endoglycosidase from *Enterococcus faecalis* with activity on human immunoglobulin G and ribonuclease B. *J Biol Chem* 279, 22558-22570
19. Garbe J, Sjögren J, Cosgrave EF et al (2014) EndoE from *Enterococcus faecalis* hydrolyzes the glycans of the bio-film inhibiting protein lactoferrin and mediates growth. *PLoS One* 9, e91035
20. Renzi F, Manfredi P, Mally M, Moes S, Jenö P and Cornelis G (2011) The N-glycan glycoprotein deglycosylation complex (Gpd) from *Capnocytophaga canimorsus* deglycosylates human IgG. *PLoS Pathog* 7, 17
21. Ding J, Pan X, Du L et al (2019) Structural and functional insights into host death domains inactivation by the bacterial arginine GlcNAcyltransferase effector. *Mol Cell* 74, 922-935
22. Gao X, Wang X, Pham TH et al (2013) NleB, a bacterial effector with glycosyltransferase activity, targets GAPDH function to inhibit NF- κ B activation. *Cell Host Microbe* 13, 87-99
23. Scott NE, Giogha C, Pollock GL et al (2017) The bacterial arginine glycosyltransferase effector NleB preferentially modifies Fas-associated death domain protein (FADD). *J Biol Chem* 292, 17337-17350
24. Jank T, Bogdanović X, Wirth C et al (2013) A bacterial toxin catalyzing tyrosine glycosylation of Rho and deamidation of Gq and Gi proteins. *Nat Struct Mol Biol* 20, 1273-1280
25. Belyi Y, Niggeweg R, Opitz B et al (2006) *Legionella pneumophila* glucosyltransferase inhibits host elongation factor 1A. *Proc Natl Acad Sci U S A* 103, 16953-16958
26. Tzivelekidis T, Jank T, Pohl C et al (2011) Aminoacyl-tRNA-charged eukaryotic elongation factor 1A is the bona fide substrate for *Legionella pneumophila* effector glucosyltransferases. *PLoS One* 6, e29525
27. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A and Minton NP (2010) The role of toxin A and toxin B in *Clostridium difficile* infection. *Nature* 467, 711-713
28. Aktories K, Schwan C and Jank T (2017) *Clostridium difficile* toxin biology. *Annu Rev Microbiol* 71, 281-307
29. Yang M, Li FG, Xie XS, Wang SQ and Fan JM (2014) CagA, a major virulence factor of *Helicobacter pylori*, promotes the production and underglycosylation of IgA1 in DAKIKI cells. *Biochem Biophys Res Commun* 444, 276-281
30. Zhu TT, Wang L, Wang HL, He Y, Ma X and Fan JM (2016) *Helicobacter pylori* participates in the pathogenesis of IgA nephropathy. *Ren Fail* 38, 1398-1404
31. Vaishnav S, Hooper LV (2007) Alkaline phosphatase: keeping the peace at the gut epithelial surface. *Cell Host Microbe* 2, 365-367
32. Yang WH, Heithoff DM, Aziz PV et al (2017) Recurrent infection progressively disables host protection against intestinal inflammation. *Science* 358, eaao5610
33. Yang WH, Heithoff DM, Aziz PV et al (2018) Accelerated aging and clearance of host anti-inflammatory enzymes by discrete pathogens fuels sepsis. *Cell Host Microbe* 24, 500-513
34. Barel M, Harduin-Lepers A, Portier L, Slomianny MC and Charbit A (2016) Host glycosylation pathways and the unfolded protein response contribute to the infection by *Francisella*. *Cell Microbiol* 18, 1763-1781
35. Goto Y, Obata T, Kunisawa J et al (2014) Innate lymphoid cells regulate intestinal epithelial cell glycosylation. *Science* 345, 1254009
36. Goto Y, Uematsu S and Kiyono H (2016) Epithelial glycosylation in gut homeostasis and inflammation. *Nat Immunol* 17, 1244-1251
37. Pham TA, Clare S, Goulding D et al (2014) Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. *Cell Host Microbe* 16, 504-516
38. Pickard JM, Maurice CF, Kinnebrew MA et al (2014) Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. *Nature* 514, 638-641